Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell

Trial Profile

Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms B-R-ENDA; BRENDA
  • Most Recent Events

    • 28 Nov 2015 Planned number of patients changed from 100 to 77, according to European Clinical Trials Database record.
    • 07 Sep 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2010-024004-98).
    • 24 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top